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peripheral nerve sheath tumor of the scalp: two
case reports and a literature review
Jun Wang, Shao-wu Ou, Zong-ze Guo, Yun-jie Wang* and De-guang XingAbstract
Malignant peripheral nerve sheath tumors of the scalp are rare lesions of the nervous system. Only 14 cases have
been reported to date. The field of neurosurgery has struggled with diagnosing and treating these tumors. In this
report, we present two cases of giant malignant peripheral nerve sheath tumors of the scalp and retrospectively
analyze the clinical features, imaging findings, pathological features, and prognoses of these two patients. Each
underwent microsurgery and radiotherapy. In addition, based on a literature review, we discuss the diagnostic and
therapeutic strategies used to treat these unusual lesions.
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Malignant peripheral nerve sheath tumors of the scalp are
rare neoplasms of the nervous system. These tumors are
considered to be a subcategory of soft tissue sarcomas, be-
cause they arise from a peripheral nerve or nerve sheath
cells and show divergent differentiation potentials [1-3]. A
variety of terminologies, including neurofibrosarcoma,
neurogenic sarcoma, malignant schwannoma, and malig-
nant neurilemomma have been used to describe the tumor.
As defined by the World Health Organization, however, the
universal or standard terminology should be malignant per-
ipheral nerve sheath tumor [1-5]. Although the incidence
of malignant peripheral nerve sheath tumor of the scalp is
very low, it is highly malignant and is associated with poor
prognosis [1-3]. Indeed, it has always been a challenge for
neurosurgeons. In this report, we present two cases that
were diagnosed and treated as giant malignant peripheral
nerve sheath tumor of the scalp. Both patients underwent
microsurgery and radiotherapy. The pathological examina-
tions confirmed that the resected lesions were consistent
with the diagnosis of malignant peripheral nerve sheath
tumor. Therefore, we retrospectively analyzed the clinical
features, imaging findings, pathological features, and prog-
noses in each case. In addition, we reviewed the relevant* Correspondence: wyj024@vip.sina.com
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reproduction in any medium, provided the orliterature regarding diagnostic and therapeutic strategies for
treating these unusual lesions.Case presentation
Case 1 was a 35-year-old male patient. The patient came to
our hospital with swelling on the back of his head, which
he reported had existed for 18 years. He had undergone
four operations in another hospital during the past 18 years,
and it had been five years since the most recent operation.
The pathologic analysis was evaluated as malignant
schwannoma (peripheral nerve sheath tumor) after the
fourth operation. On local examination, we observed a firm,
non-compressible, non-tender, non-pulsatile swelling that
measured approximately 10 × 9 cm in the occipital region.
The middle part of the mass was necrotic with a sickening
stench (Figure 1). Generally, there were no pathologic find-
ings on the neurologic examination, and the patient’s sys-
temic and laboratory findings were normal. There were no
clinical signs or anamnestic hints suggesting neurofibroma-
tosis. No distant metastases were detected in computed
tomography (CT) scans of the chest and abdomen. Mag-
netic resonance imaging (MRI) revealed a scalp swelling
with bony and dural involvement measuring 10.07 × 9.38 ×
6.49 cm in the occipital region, which showed nearly equal
T1 and slightly long T2 signals in the lesion overall, al-
though mixed signals were observed in various portions of
the lesion. The lesion exhibited a strong signal on the fluid-td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Pre- and postoperative images of Case 1. (A) (B) Preoperative magnetic resonance imaging (MRI) scans (cross-section) of the tumor
displaying an equal T1 signal with partial enhancement and extradural extension. (C) (D) Preoperative MRI scans (sagittal-section) showing a
partially contrast-enhancing extradural tumor in the occipital region with skull erosion. (E) (F) MRI fluid-attenuated inversion recovery (Flair) scan
demonstrating that the lesions primarily displayed high-intensity signals. (G) Three-dimensional computed tomography (3-D CT) of cranium bone
revealing an adjacent bone defect measuring 2.1 × 1.8 cm in the occipital area. (H) Magnetic resonance venography (MRV) demonstrating local
compression in the right transverse sinus. (I) (J) Intraoperative image revealing that the middle part of the tumor was necrotic. A latissimus dorsi
myocutaneous flap being planed to reconstruct the defect of the scalp. (K) (L) Intraoperative image demonstrating that the tumor attached to
the transverse sinus was detached completely and the bone involved was also excised. The scalp defect after tumor excision measured
approximately 12 × 12 cm. (M) (N) After large-mass excision, the scalp defect being reconstructed using a latissimus dorsi myocutaneous flap
with a muscle cuff along with the vascular pedicle. The artery and vein of the flap being anastomosed with the right superficial temporal artery
and vein. (O) Postoperative pathological examination of the tumor. Hematoxylin and eosin (H&E) staining demonstrates that the tumor cells were
spindle-shaped, with variable mitotic activity and nuclear pleomorphism (×200). (P) Strong, positive immunoreactivity to the antibody
vimentin (×200).
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eous enhancement (Figure 1). Magnetic resonance venog-
raphy (MRV) demonstrated local compression in the right
transverse sinus. Three-dimensional computed tomography
(3-D CT) of the cranium bone revealed an adjacent bonedefect that measured 2.1 × 1.8 cm in the occipital area
(Figure 1).
The patient underwent an occipital craniotomy and
plastic and reconstructive surgery in one stage. The bone
involved and a 2-cm margin of healthy tissue were
Wang et al. World Journal of Surgical Oncology 2013, 11:269 Page 3 of 8
http://www.wjso.com/content/11/1/269excised together with the swelling. The tumor, which
was attached to the dura and transverse sinus, was de-
tached completely. Generally, the lesion was totally ex-
cised. Cranioplasty was not required because the bony
defect was small (< 3 cm). After excising the large mass,
the scalp defect was approximately 12 × 12 cm. Recon-
struction was completed using a latissimus dorsi
myocutaneous flap with a muscle cuff along with the
vascular pedicle (Figure 1). The wound healed well, and
no surgical complications arose. After the surgery, the
diagnosis of malignant peripheral nerve sheath tumor
was made through postoperative pathological examin-
ation. Light microscopy revealed that the tumor cells
were spindle-shaped, with variable mitotic activity and
nuclear pleomorphism (Figure 1). Focal hemorrhage and
necrosis were also observed. Immunohistochemistry
revealed positive immunoreactivity with vimentin
(Figure 1), CD34 blood vessels, β-catenin, and ki67 (ap-
proximately 5%). The tumor was not immunoreactive
with Sangtec 100 (S-100), cell keratin (CK), SMA, bcl-2,
or resmin. Postoperatively, local radiotherapy was ad-
ministered (60 Gy/30 d, 8 weeks after surgical excision).
There was no recurrence at 20-month follow-up.
Case 2 was a 72-year-old female patient who presented
with a swelling in the occipital region that had been
gradually increasing for past four years. It had shown
rapid growth during the year prior to being our hospital.
Initially, the swelling was the size of a peanut. The pa-
tient had no history of trauma, fever, or infection at this
site. The swelling gradually increased in size for three
years and then experienced rapid growth over the next
year. On examination, we found a globular (goose egg
size), non-tender, non-compressible, firm to fluctuant
swelling measuring approximately 10 × 10 cm in the oc-
cipital region (Figure 2). A cranial computed topography
(CT) scan (one year prior to coming to our hospital) re-
vealed a lesion that exhibited higher density to the brain
parenchyma, with an adjacent bony defect measuring
4 × 4 cm in the occipital area (Figure 2). Magnetic res-
onance imaging (MRI) revealed a swelling with bony
and dural involvement measuring 10.2 × 9. 8 × 6.7 cm
in the occipital region, which showed nearly equal T1
and T2 signals. Mixed signals were also observed in vari-
ous portions of the lesions, with partial enhancement in
the lesion overall (Figure 2). The patient’s laboratory and
systemic findings (including CT scans of the chest and
abdomen) were normal. The tumor was misdiagnosed as
a meningioma in the occipital area before surgery. Dur-
ing the surgery, the lesion was found to be firm and
gray-brown in color. The intraoperative frozen sections
were pathologically examined, and the tumor’s malig-
nancy was confirmed. The lesions attached to the dura
and sinus could not be detached completely because of
bleeding from the transverse sinus. Still, the vastmajority of the tumor was resected, and then the re-
sidual tumor was coagulated using bipolar coagulation
forceps under the microscope (Figure 2).
After the surgery, the diagnosis of malignant periph-
eral nerve sheath tumor was confirmed through postop-
erative pathological examination. Light microscopy
revealed that the tumor consisted of a diffuse or fascicu-
lar proliferation of long or short spindle-shaped cells,
with moderately pleomorphic nuclei. Mitotic figures were
common (Figure 2). Immunohistochemistry revealed posi-
tive immunoreactivity with Sangtec 100 (S-100), vimentin
(Figure 2), CD34 blood vessels, CK, and ki67 (<5%). The
tumor was not immunoreactive with GFAP or HMB-45.
Two weeks after surgery, the patient was transferred to the
Department of Radiation Oncology for local radiotherapy
(59.4 Gy/33 d). In this case, the tumor recurred at nine
months follow-up. The patient refused additional treatment
because of her physical condition and poor prognosis. The
patient was still alive at 15 months follow-up, but failed to
follow up thereafter.
Discussion
The epidemiology of malignant peripheral nerve sheath
tumor
Malignant peripheral nerve sheath tumor (MPNST) is a
malignant spindle-cell tumor arising from a peripheral
nerve or showing a peripheral nerve differentiation.
MPNST is a rare tumor with an incidence of approxi-
mately 0.01% in the general population [2,3], with slight
male predominance and accounting for 5 to 10% of all
soft tissue sarcomas [1,3]. MPNST is located mainly in
the trunk and extremities, such as the buttocks, thighs,
brachial plexus, sciatic nerve, and paraspinal region. Pri-
mary scalp MPNST is extremely rare, with only 14 cases
reported to date in English literature (Table 1) [6-18].
MPNST is considered to be associated with gene muta-
tions, such as loss of the neurofibromatosis 1 gene pro-
tein product (neurofibroma) [13] and rearrangements of
the p16 (INK4A) gene [12,14]. It has been reported that
approximately one-third of MPNSTs arise de novo,
whereas nearly 60% of all MPNSTs represent a sarcoma-
tous degeneration of a benign neurofibroma. The re-
mainder (approximately 10%) may be related to previous
radiation at the tumor site [13,19,20].
Theoretically, MPNST of the scalp can originate from
any site on the scalp. Of the 16 reported cases (including
our patients, Table 1), however, the occipital region
seemed to be the most common site, accounting for
more than 50% (7 of 13, no reference in three cases). In
addition, other sites, including the parietal (4 of 13),
frontal (1 of 13), and temporal (1 of 13) regions were
also tumor locations. Of the 16 cases (Table 1), the ratio
of men to women was 10:5 (unavailable in one case),
and the patients were aged 35 to 89 (mean age of 56).
Figure 2 (See legend on next page.)
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Figure 2 Pre- and postoperative images of Case 2. (A) (B) Preoperative axial computed tomography (CT) scans (one year before admission)
showing a high-density lesion with partial destruction of occipital cranium. (C) (D) Preoperative axial magnetic resonance imaging (MRI) scans
(admission) of the tumor displaying a nearly equal T1 signal (partially high signal) with peripheral enhancement and extradural extension. The
swelling experienced a spurt in growth over one year. (E) (F) Preoperative sagittal MRI scans showing a contrast-enhancing lesion in the occipital
region with dural and bony involvement. (G) Preoperative axial MRI scan of the tumor displaying mixed T2 signals. (H) The skin incision during
the operation. (I) (J) Postoperative CT scans demonstrating that the tumor was nearly completely resected. (K) Postoperative pathological
examination of the tumor. Hematoxylin and eosin (H&E) staining revealed that the tumor consisted of a diffuse or fascicular proliferation of
spindle-shaped cells. Mitotic figures were common (×200). (L) Strong, positive immunoreactivity to the antibody vimentin (×200).
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available in three cases). Because the total number of
cases of MPNST of the scalp reported to date is still
small, the results concluded above need further
verification.
The clinical features of MPNST of the scalp
The initial clinical features of MPNST of the scalp are
generally atypical. Most patients present with a gradually
increasing swelling in the scalp (cutaneous or subcutane-
ous) [6-18]. On local examination, the swelling is com-
monly globular, firm, non-tender, non-compressible and
non-pulsatile. Initially, the swelling is the size of a pea-
nut or chestnut and then gradually increases in size. The
growth of MPNST of the scalp arising de novo, however,
occurs relatively rapidly. The tumor may invade scalp,
cranium bone, and dura at the tumor site, showing
superficial erosions in the scalp, destruction of the cra-
nium bone, and involvement of the dura (extraduralTable 1 Literature review of studies of malignant peripheral n
Study Sex/age Tumor location Neurofibromatosis
type 1
Bo
George [6] F/56 Occipital No NA
M/50 Temporal Yes NA
Dabski [7] NA/NA Scalp No NA
Kikuchi [8] M/59 Frontal No NA
Demir [9] M/80 Parietal No No
Garg [10] M/50 Occipital NA Ye
Williams [11] F/75 Scalp No NA
Fukushima [12] M/38 Occipital No No
Kumar [13] M/36 Occipital No Ye
Ge [14] M/52 Parietal Yes Ye
Hasturk [15] M/44 Occipital NA No
Shintaku [16] F/59 Scalp Yes NA
Voth [17] M/89 Parietal No No
Jhawar [18] F/43 Parietal NA Ye
Present cases M/35 Occipital No Ye
F/72 Occipital No Ye
AWD, alive with disease; CT, chemotherapy; DOD, dead of disease; Exc, excision; NA
adjuvant radiotherapy.extension or sinus invasion). In tumors arising from sar-
comatous degeneration of a benign neurofibroma,
growth is relatively slow at the beginning and then be-
comes rapid in the last several months, suggesting ma-
lignant transformation in a relatively and previously
benign tumor [13,19]. Hemorrhage and cystic degener-
ation in the tumor may also enlarge the lesion rapidly
[15]. Symptoms of headache, vomiting, seizures, vertigo,
visual impairment, or focal neurological deficits may
affect patients with giant MPNST of the scalp based on
the intracranial extension of the tumor.
The imaging features of MPNST of the scalp
Although MPNSTs of the scalp generally lack specificity
on imaging features at the early stage, CT or MRI scans
are useful for demonstrating the relationship with sur-
rounding structures. They may display high, equal, or
low densities when the CT scans are enhanced. On MRI




+ Exc + RT 4 m, AWD
+ Exc + RT 11 y, NED
NA Exc NA
+ Exc 5 y, NED
+ Exc + RT 6 m, NED
s + Exc + RT NA
+ CT+Exc 2 y, NED
+ Exc 4 m, DOD
s + Exc + RT 28 m, NED
s + Exc 6 m, NED
+ Exc NA
_ Exc 18 m, DOD
+ Exc + RT 14 m, AWD
s NA Exc 1 y, NED
s _ Exc + RT 20 m, NED
s + Exc + RT 9 m (Re);
15 m, AWD
, not available; NED, no evidence of disease; Re, recurrence; RT,
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weighted and Flair sections [20]. Enhancing the lesion
may be homogeneous, inhomogeneous, partial, periph-
eral, moderate, or dense according to the vascular dens-
ities [15,20]. Magnetic resonance venography (MRV)
may be done to plan surgery for in patients with tumors
located adjacent to the sinus. MRI scans often reveal fea-
tures of MPNSTs that differ from those of other scalp
tumors, such as lipoma and malignant melamoma. Tu-
mors with cystic degeneration, hemorrhage, or calcifica-
tion, however, may show mixed densities on CT or MRI
scans, which contributes to the high chance of misdiag-
nosis. Of the two cases in our group (especially for
Case #1, with the middle part of the tumor necrotic),
MRI scans demonstrated mixed densities in T1- and T2-
weighted series and inhomogeneous enhancement in
contrast series. Case #2 was misdiagnosed as having ma-
lignant meningioma, and this mistake was not discov-
ered until the surgery. We have confirmed that it is
difficult to clinically diagnose MPNST of the scalp and
the diagnosis of the disease relies on intraoperative and
postoperative pathological findings.
The pathological features of MPNST of the scalp
Pathological diagnosis is the gold standard for diagnos-
ing MPNST of the scalp. Most examples of MPNST
show differentiation toward Schwann cells, but MPNSTs
that exhibit perineurial cells and endoneurial fibroblasts
have also been reported [16]. Although MPNST is a het-
erogeneous group of neoplasms that shows diverse dif-
ferentiation potential, routine hematoxylin-eosin (H&E)
and immunohistochemical staining techniques can help
diagnose the majority of MPNSTs of the scalp. H&E
staining can reveal the overall morphology of the tumor
cells. Under a light microscope, the cells are polygonal
or spindle-shaped and exhibit signs of mitosis and nu-
clear pleomorphism. Focal hemorrhage and necrosis are
also seen frequently [3,8,10,16,19]. Immunohistochemi-
cal staining of the tumor tissue with a variety of anti-
bodies can diagnose the disease and differentiate it from
other diseases. The S-100, EMA, Vimentin (VIM), and
CD34 antibodies are highly specific to MPNST of the
scalp [3,16,19,21]. For most MPNST cases, tumor cells
exhibit differentiation toward Schwann cells, which is
represented by immunoreactivity for S-100 protein and
ultrastructurally by the presence of long cytoplasmic
processes that are closely invested by a well-formed
basal lamina. In some MPNST cases, tumor cells differ-
entiate toward perineurial cells, evidenced by immunore-
activity for EMA and ultrastructurally by the presence of
tight junctions, abundant pinocytotic vesicles, and an
interrupted basal lamina. If tumor cells are not immuno-
reactive for either the S-100 protein or EMA, but are
positive for vimentin, CD10, and CD34, these cells areconsidered to correspond to endoneurial fibroblasts [16].
Of the 16 cases (Table 1), 12 were immunoreactive for
the S-100 protein (12 of 14 cases (86%); not available in
two cases), suggesting a high specificity. Of the two cases
whose tumor cells were not immunoreactive for the S-
100 protein, one case was in our group, and his tumor
cells were positive for CD34 and vimentin, suggesting
the tumor is not conventional Schwann cell-derived
MPNST. S-100-negative MPNSTs are uncommon. As
mentioned above, perineurial cells are typically positive
for EMA and negative for S-100 protein, while
endoneurial fibroblasts are negative for either the S-100
protein or EMA. Other markers, such as glial fibrillary
acidic protein (GFAP), cell keratin (CK) and HMB, are
usually not expressed in MPNST of the scalp and are
therefore used only as references. In general, a combin-
ation of antigens is used to help exclude other scalp tu-
mors and to confirm the diagnosis of MPNST.
Comprehensive treatment of MPNST of the scalp
The current treatment of these highly malignant tumors
does not guarantee an optimistic prognosis. Surgery and
local radiation therapy are currently administered to
treat the disease [2-4,6-18,22,23]. Other therapies, such
as chemotherapy and immunotherapy, which are usually
limited to treating metastatic diseases, are still being
evaluated [3,10]. The International Consensus Group
has recommended that the current management of
MPNST should be identical to that of any other soft tis-
sue tumors [18]. Surgery, therefore, is the mainstay of
treatment for MPNST of the scalp. The goal of surgery
is to achieve complete excision of the tumor with wide
(negative) margins (≥2cm) [13,17,18]. After a large mass
is excised, scalp defects are common, and reconstruction al-
ways needs to be done using cutaneous or myocutaneous
flaps (plastic and reconstructive surgery), such as was com-
pleted in Case #1 in our group. From a practical standpoint,
the bone and dura involved should be resected together in
order to avoid recurrence. When the tumor has invaded
the sinus, however, total resection may be impossible due
to severe bleeding in the surgery. In this case, remnants of
the tumor are unavoidable, such as occurred in Case #2 in
our group. Thus, as some authors have pointed out, local
recurrence and disease-related deaths may be likely to be
more frequent for giant MPNST of the scalp, especially in
cases with high-grade tumors, incomplete surgical excision,
and intracranial tumor extension [17].
As reported, surgical excision followed by adjuvant
radiotherapy can improve local control [17,23]. Thus,
some authors have recommended that adjuvant radio-
therapy should been considered for all intermediate- and
high-grade MPNST of the scalp, as well as low-grade tu-
mors with positive margins [13,18]. We agree with the
assessment that radical excision with wide margins (≥2
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vant radiation should be considered as a standard treat-
ment for these malignant tumors [17]. Of the 16 cases
(Table 1), surgical excision followed by adjuvant radio-
therapy had been done in eight cases. After therapy,
eight patients were (50%) alive and had no evidence of
recurrence or metastasis after follow-up periods of six
months to 11 years. Only two of the patients died due to
metastatic disease [12,16]. It seems that the current
treatment of these highly malignant tumors, however, is
not that pessimistic. As some authors have pointed out,
the survival rates of patients with MPNSTs were signifi-
cantly better for superficial tumors, such as MPNST of
the scalp [5]. Other authors, however, believe that the
present data does not allow final conclusions about the
prognosis of MPNST of the scalp, because these results
are based on a small patient population with primarily
short follow-up periods [17]. Therefore, further studies
with greater numbers of patients are required to confirm
the prognosis for MPNST of the scalp.Conclusions
In conclusion, in this paper, we have described two cases
of MPNSTs of the scalp. The diagnosis of MPNST of the
scalp is based on integrating clinical, imaging, histo-
pathological, and immunohistochemical findings. Con-
sidering the high malignance and invasive growth of
MPNST of the scalp, radical excision with wide margins
(≥2 cm), histologic control of resection borders, and
adjuvant radiation should be considered standard
treatment.Consent
Written informed consents were obtained from the pa-
tients for publication of this Case report and any accom-
panying images. Copies of the written consent are
available for review by the Editor-in-Chief of this
journal.
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